The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Optimizing neoadjuvant approaches in pancreatic ductal adenocarcinoma
Michele Reni, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the need to optimize neoadjuvant approaches in patients with pancreatic ductal adenocarcinoma (PDAC). Prof. Reni suggests considering maintenance therapy after surgery as a potential strategy to improve outcomes, and plans to explore this idea in future trials. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Three years event-free survival with the best regimen is around 30%. So, of course, we need improvement there. But nowadays we don’t have new drugs ready for prime time. So, what we can do is try to improve our strategy. One possibility is to consider giving maintenance therapy after surgery in this population. So, we are thinking about planning this kind of trial for the future...
Three years event-free survival with the best regimen is around 30%. So, of course, we need improvement there. But nowadays we don’t have new drugs ready for prime time. So, what we can do is try to improve our strategy. One possibility is to consider giving maintenance therapy after surgery in this population. So, we are thinking about planning this kind of trial for the future.
Read more...
